Royal Bank of Canada Reduces Stock Position in AptarGroup, Inc. (NYSE:ATR)

Royal Bank of Canada cut its stake in AptarGroup, Inc. (NYSE:ATR – Get Rating) by 2.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 175,183 shares of the industrial products company’s stock after selling 4,429 shares during the period. Royal Bank of Canada owned approximately 0.27% of AptarGroup worth $16,647,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. lifted its holdings in AptarGroup by 76.3% in the third quarter. Rockefeller Capital Management L.P. now owns 328 shares of the industrial products company’s stock valued at $31,000 after acquiring an additional 142 shares during the last quarter. CWM LLC lifted its holdings in AptarGroup by 58.3% in the third quarter. CWM LLC now owns 551 shares of the industrial products company’s stock valued at $52,000 after acquiring an additional 203 shares during the last quarter. Ellevest Inc. lifted its holdings in AptarGroup by 107.5% in the third quarter. Ellevest Inc. now owns 606 shares of the industrial products company’s stock valued at $58,000 after acquiring an additional 314 shares during the last quarter. Eagle Bay Advisors LLC lifted its holdings in AptarGroup by 141.7% in the second quarter. Eagle Bay Advisors LLC now owns 776 shares of the industrial products company’s stock valued at $80,000 after acquiring an additional 455 shares during the last quarter. Finally, Wipfli Financial Advisors LLC acquired a new position in AptarGroup in the third quarter valued at approximately $92,000. 89.37% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on ATR shares. StockNews.com upgraded AptarGroup from a “hold” rating to a “buy” rating in a research note on Tuesday, February 28th. Wells Fargo & Company upped their price target on AptarGroup from $121.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 21st. Deutsche Bank Aktiengesellschaft upped their price target on AptarGroup from $125.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, February 21st. TheStreet upgraded AptarGroup from a “c+” rating to a “b-” rating in a research note on Tuesday, January 17th. Finally, Robert W. Baird upped their price target on AptarGroup from $105.00 to $115.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 21st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, AptarGroup has an average rating of “Moderate Buy” and a consensus target price of $122.33.

Insider Activity at AptarGroup

In related news, Director Maritza Gomez Montiel sold 1,500 shares of the stock in a transaction on Tuesday, February 21st. The stock was sold at an average price of $114.67, for a total value of $172,005.00. Following the transaction, the director now owns 4,024 shares of the company’s stock, valued at $461,432.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Robert Kuhn sold 64,560 shares of the stock in a transaction on Tuesday, February 21st. The stock was sold at an average price of $114.04, for a total value of $7,362,422.40. Following the transaction, the chief financial officer now owns 54,044 shares of the company’s stock, valued at $6,163,177.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Maritza Gomez Montiel sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, February 21st. The stock was sold at an average price of $114.67, for a total value of $172,005.00. Following the transaction, the director now directly owns 4,024 shares in the company, valued at approximately $461,432.08. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

AptarGroup Stock Down 2.8 %

Shares of NYSE ATR opened at $116.83 on Tuesday. The stock has a market cap of $7.64 billion, a P/E ratio of 32.63, a PEG ratio of 4.46 and a beta of 0.63. The company has a current ratio of 1.56, a quick ratio of 1.03 and a debt-to-equity ratio of 0.51. AptarGroup, Inc. has a 12-month low of $90.23 and a 12-month high of $122.30. The business’s fifty day simple moving average is $113.36 and its 200-day simple moving average is $106.32.

AptarGroup (NYSE:ATR – Get Rating) last announced its quarterly earnings data on Friday, February 17th. The industrial products company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.13. The business had revenue of $795.91 million for the quarter, compared to analysts’ expectations of $775.57 million. AptarGroup had a return on equity of 12.78% and a net margin of 7.20%. The company’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period last year, the firm earned $0.93 earnings per share. As a group, equities analysts predict that AptarGroup, Inc. will post 3.85 EPS for the current fiscal year.

AptarGroup Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 23rd. Investors of record on Thursday, February 2nd were issued a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 1.30%. The ex-dividend date of this dividend was Wednesday, February 1st. AptarGroup’s dividend payout ratio (DPR) is presently 42.46%.

About AptarGroup

(Get Rating)

AptarGroup, Inc engages in the design, manufacture, drug delivery, consumer product dispensing, sealing and active packaging solutions and services for the prescription drug, consumer health care, injectables, active packaging, beauty, personal care, home care, and food and beverages. It operates through the following business segments: Beauty & Home, Pharma and Food & Beverage.